XML 43 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 24, 2023
Sep. 25, 2022
Cash flows from operating activities:    
Net income $ 188,106 $ 901,580
Adjustments to reconcile net income to cash provided by operating activities:    
Depreciation and amortization 307,414 300,962
Deferred income tax benefit (46,808) (48,611)
Gain on property disposals (8,416) (5,620)
Loan cost amortization 6,059 4,311
Stock-based compensation 5,236 5,982
Asset impairment 4,011 0
Accretion of discount related to Senior Notes 1,581 1,288
Loss on equity-method investments 330 1
Changes in operating assets and liabilities:    
Trade accounts and other receivables (65,183) (211,827)
Inventories (12,957) (455,465)
Prepaid expenses and other current assets (8,039) (3,525)
Accounts payable, accrued expenses and other current liabilities 12,224 297,271
Income taxes 40,463 10,241
Long-term pension and other postretirement obligations (1,700) (3,128)
Other operating assets and liabilities (22,723) (2,847)
Cash provided by operating activities 399,598 790,613
Cash flows from investing activities:    
Acquisitions of property, plant and equipment (432,339) (342,588)
Proceeds from insurance recoveries 20,681 7,339
Proceeds from property disposals 17,188 14,607
Purchase of acquired business, net of cash acquired 0 (9,692)
Cash used in investing activities (394,470) (330,334)
Cash flows from financing activities:    
Proceeds from revolving line of credit and long-term borrowings 1,278,032 362,541
Payments on revolving line of credit, long-term borrowings and finance lease obligations (765,899) (370,332)
Payments of capitalized loan costs (10,275) (3,070)
Payment of equity distribution under Tax Sharing Agreement between JBS USA Holdings and Pilgrim’s Pride Corporation (1,592) (1,961)
Purchase of common stock under share repurchase program 0 (199,553)
Cash provided by (used in) financing activities 500,266 (212,375)
Effect of exchange rate changes on cash and cash equivalents (1,036) (13,932)
Increase in cash, cash equivalents, restricted cash and restricted cash equivalents 504,358 233,972
Cash, cash equivalents, restricted cash and restricted cash equivalents, beginning of period 434,759 450,121
Cash, cash equivalents, restricted cash and restricted cash equivalents, end of period $ 939,117 $ 684,093